Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044837 | 0.77 | EPHX2 (0.38) | EPHX1FAAHEPHX2L3MBTL1KCNA5 | |
| SCHEMBL7042125 | 0.72 | L3MBTL1 (0.39) | EPHX1L3MBTL1KCNA5POLB | |
| SCHEMBL6463625 | 0.70 | KCNJ6 (0.36) | FAAHEPHX2 | |
| SCHEMBL7049043 | 0.70 | MAPT (0.38) | L3MBTL1 | |
| SCHEMBL6466202 | 0.69 | LMNA (0.36) | FAAHPOLB | |
| SCHEMBL7047959 | 0.69 | MEN1 (0.44) | FAAHEPHX2 | |
| SCHEMBL7042863 | 0.67 | KCNA5 (0.37) | EPHX1KCNA5 | |
| SCHEMBL7049145 | 0.66 | KCNA5 (0.38) | L3MBTL1KCNA5 | |
| SCHEMBL27823605 | 0.66 | FAAH (0.53) | EPHX1FAAHEPHX2KCNA5MGLL | |
| SCHEMBL7046555 | 0.65 | SLC1A3 (0.36) | L3MBTL1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | EPHX1 593/4885FAAH 479/4885EPHX2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.